| Company/Division name | Cidara Therapeutics |
| Parent company | Cidara Therapeutics |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2025 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 338 |
| City reshored to: | San Diego |
| State(s) reshored to: | CA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | biopharmaceuticals; CD388 |
| What domestic positive factors made reshoring more attractive? | Government Incentives, Proximity to customers/market |
| Government Incentive dollar amount: | 338,000,000 |
